// App-Quantinova.ai

556 : The detection of viable human circulating tumor cells (v-hCTCs) in resectable pancreatic cancer induced by neoadjuvant chemoradiotherapy (NACRT) using gemcitabine, S-1 and intensity-modulated radiotherapy (IMRT)

Researchers

Presenter

  • Masahiro Tanemura

Principal Investigators

  • Toshimitsu Irei

  • Masashi Inoue

  • Masaki Mori

  • Yuichiro Doki

  • Shinya Yamashita

  • Kenta Furukawa

  • Masaki Wakasugi

  • Kentaro Kishi

  • Hiroaki Nagano

  • Hiroki Akamatsu

  • Yasuo Urata

  • Nobuyoshi Hatanaka

Medical Centers

  • Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan

  • Osaka Rousai Hospital, Osaka, Japan

  • Osaka University Graduate School of Medicine, Suita, Japan

Locations

  • Japan

Companies

  • Oncolys BioPharma In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

  • Hürthle cell carcinoma

Biomarkers

  • Carbohydrate antigen 19-9

  • Circulating tumor cells

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • Gemcitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved